Tampa, FL – According to filings with the U.S. Securities and Exchange Commission, Betaliq Inc. is raising $10,000,000.00 in a new round of investment. Sources indicate as part of senior management President, Barry Butler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Betaliq Inc.

Betaliq was formed to develop ophthalmic beta blockers using Novaliq’s patented EyeSol non-water formulation technology. Betaliq is developing two beta blockers, for the treatment of glaucoma. BTQ 1901 is an EyeSol based formulation of a potent selective beta blocker that has not previously been used to treat glaucoma. BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker.

To learn more about Betaliq Inc., visit http://www.betaliq.com/

Contact:
Barry Butler, President
813-766-9539

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved